Skip to main content

Invitrogen Completes Acquisition of BioReliance for $403.2 Million

NEW YORK, Feb. 10 (GenomeWeb News) - Carlsbad, Calif.-based Invitrogen yesterday announced the closing of its acquisition of BioReliance in an all-cash deal conducted through its subsidiary entity, Baseball Acquisition.

BioReliance, a Rockville, Md.-based contract service organization, will operate as a wholly-owned subsidiary of Invitrogen. The firm in January announced that it would close a 44-employee Worchester, Mass., facility it acquired with a merger with Q-One Biotech in September.

BioReliance shares were delisted from the Nasdaq exchange, and ceased trading at the close of business on Friday, Feb. 6.

Invitrogen announced in December that it would acquire BioReliance for $500 million. Invitrogen paid $48 per share for BioReliance's approximately 8.4 million shares, valuing today's transaction at $403,200,000.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.